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cirrhosis and ascites, in order to intervene early and prevent
further deterioration to a point where resolution becomes less
certain and prognosis adverse.
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OpeReply to: ‘‘To close the stable door before the horse has bolted’’To the Editor:
We read with great interest the letter by Thalheimer and
Burroughs in relation to our study and that of Piano et al. [1,2]
recently published in Journal of Hepatology. We appreciate their
interesting and stimulating comments as they contribute to
scientiﬁc interaction on a very important topic. We absolutely
agree with their comment that the results of our study should
be interpreted in the perspective that patients were hospitalized
in a Liver Unit and complications of cirrhosis were managed
according to international guidelines [3]. Having said that, one
of the main messages of our study is that in cirrhosis AKI stage
1 group is constituted by a heterogeneous population with
respect to prognosis, and that two very different subsets of
patients can be easily identiﬁed according to peak serum creati-
nine reached during the AKI episode. A ﬁrst subgroup, AKI stage
1a with a peak serum creatinine 61.5 mg/dl, that has a 3-month
survival close to that of patients without AKI, and a second sub-
group, AKI stage 1b, with a peak serum creatinine >1.5 mg/dl.
Patients from this latter group have a much worse prognosis,
which is intermediate between those of patients without AKI
and patients with stage 2 AKI. In our study, it is not stated that
AKI stage 1a is a benign condition. A simple look at Fig. 3 (graph
A) of the study by Fagundes et al. [1] shows that 3-month prob-
ability of survival in the group of patients with AKI stage 1a is
of 84%, which is not really a prognosis of a ‘‘benign’’ condition.
The incorporation of a maximum level of serum creatinine
reached (such as the 1.5 mg/dl used in our study) to the AKI cri-Journal of Hepatology 20
n access under CC BY-NC-ND license.teria makes pathophysiological sense because it adds a threshold
to deﬁne kidney dysfunction. As an example, let’s imagine two
patients with baseline serum creatinine of 0.5 mg/dl and
1.3 mg/dl respectively, who develop AKI stage 1 based on an
increase of 0.3 mg/dl in both cases. While in the former a peak
of serum creatinine of 0.8 mg/dl indicates that glomerular ﬁltra-
tion rate is still normal, in the latter a peak of 1.6 mg/dl indicates
impaired organ function (markedly reduced glomerular ﬁltra-
tion). At these levels of glomerular ﬁltration rate, the minimum
GFR reached (which corresponds to the peak serum creatinine)
has more prognostic information than a relative increase of
0.3 mg/dl. This statement is not opinion-based, it is based on data
from two different prospective studies that included a large
number of patients.
In summary, the studies by Piano et al. and Fagundes et al.
[1,2] convincingly demonstrate, in 2 independent series of
patients, that the incorporation of a peak serum creatinine of
1.5 mg/dl in stage 1 of the AKIN criteria provides very useful clin-
ical information in cirrhosis as it allows stratifying these patients
into two different subgroups with markedly different prognosis.
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To close the stable door on time in order to save all horses
avoiding pointless panic
To the Editor:
We want to thank Thalheimer et al. for their interest in our study
and the Fagundes study recently published in Journal of Hepatol-
ogy regarding the application of acute kidney injury network
(AKIN) criteria in the diagnosis of acute kidney injury (AKI) in
patients with cirrhosis and ascites [1,2]. In their letter Thalheimer
et al. highlighted that although patients with stage 1 AKI and
serum creatinine (sCr) <1.5 mg/dl did not show a higher mortal-
ity rate with respect to patients without AKI, stage 1 AKI with a
sCr <1.5 mg/dl should not be considered a benign condition [3].
We are in agreement with Thalheimer et al. and we did not
deﬁne it as a benign condition. Currently, there is no evidence that
AKI stage 1 with a ﬁnal value lower than 1.5 mg/dl is associated
with a higher hospital and or 90-day mortality rate in patients
with cirrhosis [1,2,4]. Furthermore, in our study, patients with
AKI stage 1 and sCr <1.5 mg/dl had a low rate of progression
of AKI stage and a high rate of resolution of AKI. Nevertheless,
an AKI with these features is associated with an increase in the
medium-term mortality [5]. Therefore, the question is not if to
treat or not to treat AKI stage 1 with sCr <1.5 mg/dl, but how to
treat it in order to prevent a further renal impairment and thereby
avoid an unjustiﬁed early use of some therapeutic resources,
which are expensive and/or may induce severe adverse effects,
such as vasoconstrictors. Regarding this last point, we should
recognize that both in our study and in Fagundes’s study, almost all
patients with AKI and sCr <1.5 mg/dl were effectively treatedwith
simplemeasures: tapering orwithdrawal of diuretics, withdrawal of
nephrotoxic drugs, vasodilators or non-steroidal anti-inﬂammatory
drugs (NSAIDs), plasma volume expansion in case of dehydration,
the treatment of any bacterial infections when diagnosed.
In our opinion, these measures should be applied soon to all
patients with AKI. This is the reason why these measures were
suggested in the algorithm for the management of AKI in patients
with cirrhosis and ascites, which we recently proposed [1]. More
in detail, patients with cirrhosis and ascites with initial AKIN
stage 1 without progression and with a sCr <1.5 mg/dl should
be treated as soon as possible by the therapeutic approach previ-
ously discussed. Plasma volume expansion with albumin was
proposed in patients with initial AKIN stage higher than 1 and
in those with initial AKIN stage 1 and sCr P1.5 mg/dl or with
progression towards a higher stage in spite of the therapeutic
measures previously suggested. The further treatment of patients
who do not respond to the withdrawal of diuretics and plasma
volume expansion will depend, of course, on the ﬁnal diagnosis
of the AKI phenotype.
Therefore, summing up, this algorithm implies the following:
 The acceptance of the main point that derived from the
application of AKIN criteria that is to focus attention on
and to manage promptly even small increases in sCr.
 The maintenance of a sCr cut off value (1.5 mg/dl) not to
deﬁne AKI, but to titrate its treatment.
 A more rational application of the therapeutic resources
(avoiding the potentially dangerous consequences of an
overtreatment of AKI as a consequence of an uncritical
application of the AKIN criteria).
 A clear distinction between AKI and HRS, since HRS is only
one among the possible phenotypes of AKI.
 The deﬁnitive removal of any cut off of sCr from the
criteria for diagnosis of HRS in the setting of AKI.
This algorithm is a simple working hypothesis and large
perspective interventional studies are needed to validate it.
Nevertheless, it appears a step forward in the management of
AKI in these patients.
Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂicts of
interest with respect to this manuscript.
References
[1] Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation
of the acute kidney injury network criteria in hospitalized patients with
cirrhosis and ascites. J Hepatol 2013;59:482–489.
[2] Fagundes C, Barreto R, Guevara M, Garcia E, Sola E, Rodriguez E, et al. A
modiﬁed acute kidney injury classiﬁcation for diagnosis and risk stratiﬁcation
of impairment of kidney function in cirrhosis. J Hepatol 2013;59:474–481.
680 Journal of Hepatology 2014 vol. 60 j 676–683
